Medicinal Products


Aerius Generic Drug
Therapeutic class: Allergology
Active ingredients: Desloratadine
laboratory: Zydus France

Coated tablet
Case of 30
All forms


DESLORATADINE ZYDUS is indicated for the symptomatic treatment of:

• allergic rhinitis (see section on Pharmacodynamic properties ),

• urticaria (see section on Pharmacodynamic properties ).

Dosage DESLORATADINE ZYDUS 5 mg Film-coated tablet Case of 30

Adults and adolescents (12 years and older): one tablet once daily, at or away from meals for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section Pharmacodynamic properties ).

In adolescents aged 12 to 17 years, experience with the use of desloratadine in clinical efficacy studies is limited (see Adverse Reactions and Pharmacodynamic Properties ).

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or less than 4 weeks) should be managed based on a history of the patient's interrupted after the disappearance of symptoms, and restored to their reappearance.

In persistent allergic rhinitis (presence of symptoms over a period of 4 days or more per week and for more than 4 weeks), continuous treatment may be offered to patients during periods of allergen exposure.

Against indications

Hypersensitivity to the active substance, to any of the excipients, or to loratadine.

Undesirable effects Desloratadine Zydus

In clinical trials conducted in allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, adverse events were reported in 3% more patients than those treated with placebo. The most commonly reported adverse events with an incidence greater than placebo were: asthenia (1.2%), dry mouth (0.8%) and headache (0.6%). In a clinical study in 578 adolescent patients aged 12 to 17, the most common adverse event was headache; it occurred in 5.9% of patients treated with desloratadine and in 6.9% of patients receiving placebo. Other adverse effects reported very rarely since marketing are listed in the following table:

Psychiatric disorders


Nervous system disorders

Dizziness, drowsiness, insomnia, psychomotor hyperactivity, convulsions

Heart conditions

Tachycardia, palpitations

Gastrointestinal disorders

Abdominal pain, nausea, vomiting, dyspepsia, diarrhea

Hepatobiliary disorders

Increases in liver enzymes, increased bilirubin, hepatitis

Musculoskeletal and systemic disorders


General disorders

Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnea, pruritus, rash, and urticaria)

Popular Posts

Category Medicinal Products, Next Article